An observational study in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by General Hospital of Shenyang Military Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is one of 5 that started in 2026, is one of 7 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 31st registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 5
First in 2016; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 145 across the 27 interventional studies, 1,000 across the 7 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
11 of the studies in Ischemic Stroke by General Hospital of Shenyang Military Region that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07135089Phase 3General Hospital of Shenyang Military RegionImproving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban | 2027-09-30 |
| NCT06170944General Hospital of Shenyang Military RegionEffect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07344610General Hospital of Shenyang Military RegionEffects of Short-term Intensive Statin Therapy on Lipid Levels | 2026-12-30 |
| NCT06940128General Hospital of Shenyang Military RegionDirect Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO) | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.
patients with ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI, or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%);
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atorvastatin 40-80mg/day, Rosuvastatin 20mg/day
Absolute reduction in Low-Density Lipoprotein Cholesterol
Time frame: 7±1 days
Absolute and relative reductions in other lipid parameters (Total Cholesterol, Triglyceride, High-Density Lipoprotein Cholesterol, Lipoprotein a)
Time frame: 7±1 days
Changes in high-sensitivity C-reactive protein
Time frame: 7±1 days
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 11 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region